BIOMARKERS DISCRIMINATING THE DISCORDANT PHENOTYPES OF X-ADRENOLEUKODYSTROPHY

A research group from CIBER, IDIBELL, Institució Catalana de Recerca i Estudis Avançats and Asociación Española Contra la Leucodistrofia ELA España ha identified novel biomarkers for facilitating diagnostic of variable phenotypes of X-adrenoleukodystrophy

The Need

X-linked adrenoleukodystrophy (X-ALD) is a severe neurometabolic disease that can appear with several phenotypes with a broad clinical variable spectrum. Thus, the identification and validation of biomarkers able to discriminate across the phenotypic spectrum is an unmet, urgent need in X-ALD population.

The Solution

Identification of lipid biomarkers that can discriminate among X-ALD phenotypes in blood and brain samples.

Innovative Aspects

✓ Appropriate identification of X-ALD phenotypes
✓ Improved therapeutic management of the disease:
  • Monitoring response to treatment in clinical trials
  • Information of disease severity and prognosis to define the personalized management of each patient.

Stage of Development:
Analytic validation in human samples from healthy donors and patients

Intellectual Property:

• European patent (EP23382397) application was submitted 16 of March 2023.
• Suitable for international extension (PCT application)

Aims

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

Contact details

Consortio Centro de Investigación Biomédica en Red (CIBER)  
etc@ciberisciii.es  
https://www.ciberisciii.es/en